Drugs / SBO-154
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07042100 | Aug 2025 → Aug 2028 expected | cancer | Sun Pharma Advanced Research Company Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBO-154 | “This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country.” NCT07042100 ↗ |
| Route | Intravenous | “Administered IV every 3 weeks” NCT07042100 ↗ |